A full house presented itself when Inven2 pitched 8 of their most promising cancer research projects at Oslo Cancer Cluster Incubator June 12th. In total approximately 60 people gathered inside Oslo Cancer Cluster Innovation Park, and among the participants several experienced investors from other cancer projects. — I’m positively surprised that so many potential and […]
Øyvind Kongstun Arnesen is appointed new chairman at Oslo Cancer Cluster (OCC). On a recent General Assembly, Oslo Cancer Cluster elected Øyvind Kongstun Arnesen as new chairman after a unanimous vote. He takes over after Henrik Lund who opted not to stand for re-election after four years in the position. Øyvind is currently CEO at […]
Oslo Cancer Cluster member Immunitrack has landed investments worth millions. The money will be used to develop a computer program that can predict how the immune system will react to different substances. Already Immunitrack, co-founded by Stephan Thorgrimsen and Sune Justesen, is offering contracted research to the pharmaceutical industry predicting how the immune system react […]
Er du investor eller gründerspire? Vi trenger deg! Norge har en sterk tradisjon innen kreftforskning i verdensklasse. Basert på denne fremragende forskningen har selskaper som Algeta, Nordic Nanovector, Ultimovacs og Zelluna Immunotherapy blitt spunnet ut. Og det kommer mer. Inven2 inviterer investorer, gründerspirer og andre interesserte til en presentasjon av de mest lovende nye prosjektene […]
Our General Manager Ketil Widerberg visited the podcast People creating the future Norway (De som bygger det nye Norge) hosted by Silvija Seres and Oslo Business Forum. Ketil and Silvija discussed important issues like: Is it possible to make cancer a chronic disease? And how do you really create medicine that is tailored for each […]
Former Ullern upper secondary school student Simone Mester is enjoying a meteoric career as a researcher. Her research is aimed at making cancer drugs more efficient by getting them to stay longer in the body. But how did she end up here, and what advice does she have for upper secondary school students who are […]
Oslo Cancer Cluster member Vaccibody is making headway with their cancer vaccine technology. Now they are ready with clinical trials involving 40 patients in Germany, the first patient is already enrolled. Neoantigens Reveals Cancer Cells Cancer is famous for its ability to deceive, appearing to the immune system as normal tissue while wreaking havoc […]
For the third year running, Menon Economics presented a report on “The Value of the Norwegian Health Industry”. The conclusion: Both the industry and exports are growing substantially. We see an increase in export income, research and innovation levels. The report was launched at “Næringslivets Hus”, the home of NHO, and gathered a full house […]
Professor Harald Stenmark is granted the European Research Council’s (ERC) Advanced Grant for his cancer research. This is the second time he receives the grant; a privilege that has only befallen two other people, professor Edvard Moser (NTNU) and professor Kenneth Hugdahl (UiB). Through the grant Stenmark’s research project “Coincidence detection of proteins and lipids […]
Gentilpasset behandling har siden begynnelsen av 2000-tallet blitt beskrevet som et av de nye, viktige våpnene som kan bekjempe kreft. Hør forsker Hege G. Russnes og professor Anne Hansen Ree, her fra Cancer Crosllinks i januar i år, fortelle om deres forskningsprosjekt MetAction, og hvordan de tar i bruk gentilpasset behandling for å gi et […]
